The company acquires established and successful infusion pharmacies, entering a $42 billion market.
SAN DIEGO, May 21, 2024 (GLOBE NEWSWIRE) — Dalrada Financial Corporation (OTCQB: DFCO, “Dalrada”, the “Company”) today announced that Genefik, Inc., its wholly owned healthcare subsidiary, ”) was announced. has acquired IV Services, LLC, a recognized leader in pharmaceutical business and infusion management.
The acquisition of IV Services expands Genefic's existing pharmacy sales and scope of operations. Additionally, the acquisition will also increase Genefic's sales and strengthen its current specialty pharmacy business through new product offerings within its existing patient base and payer agreements with major insurance companies.
“The acquisition of an infusion specialist like IV Services strengthens Genefic's offering and allows us to further expand in this unique market,” said Brian Bonner, CEO of Dalrada. , which can bring immediate and long-term value to our pharmaceutical business.” “And we are pleased to report that the acquisition of these companies will not be dilutive for Dalrada shareholders,” he added.
The global infusion pharmacy management market is currently worth approximately $42 billion and is expected to grow to nearly $70 billion by 2030, and the acquisition will expand Genefic's large portfolio of Louisiana-based IV Services. You will have the opportunity to continue to develop your patient care capabilities and enter the well through our facilities. -An established and rapidly growing business segment.
Genefic CEO Dan Riley echoed Bonner's sentiments, adding: This is the first of several opportunities in the infusion pharmacy space that will give us a broader reach than ever before, while also generating significant revenue. ”
With IV Services receiving full pharmacy licenses in Louisiana and Mississippi, Genefic adds more U.S. states to its pharmaceutical footprint, including North Carolina, South Carolina, Tennessee, Georgia, Alabama, and Texas.
About Dalrada Corporation
Dalrada Financial Corporation (OTCQB: DFCO) is a multinational holding company that develops, manufactures and markets powerful products and services in the clean energy and healthcare sectors. Dalrada's core divisions include Dalrada Climate Technology, which provides cutting-edge heat pump technology for industrial and residential applications, and Genefique Specialty Pharmacy, which provides end-to-end prescription services and patient advocacy and support. It is included.
Dalrada Financial Corporation consistently drives innovation for maximum impact, creating greater value for our shareholders.
For more information, please visit www.dalrada.com or follow us on LinkedIn, Facebook, Twitter and YouTube.
About Genefic
Genefic, a wholly owned subsidiary of Dalrada Financial Corporation, proudly delivers cutting-edge health products and services through redesigned systems and reimagined patient care. Genefic's unique pharmacy solution, Genefic Specialty Pharmacy, brings over 30 years of expertise and provides patient advocacy through end-to-end prescription services, medical education, patient advocacy and support.
Forward-looking statements
Statements contained in this press release, other than statements of historical fact, include, among other things, statements regarding cost reductions and anticipated pre-tax savings from cost reduction programs, cost restructuring, footprint rationalization and streamlining of our operations. and statements about streamlining, reducing complexity, and strengthening systems. The speed with which we make decisions utilizing our procurement capabilities and the timing of implementation and completion of cost reduction programs are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. These statements are based on the following beliefs: and management's assumptions based on information available to the Company at the time such statements are made. These statements generally include words such as “will,” “believe,” “expect,” “intend,” “anticipate,” “estimate,” “anticipate,” “plan,” and “project.” ”, and similar expressions are made as of the date hereof and involve certain risks and uncertainties, and we undertake no obligation to update them. Forward-looking statements are subject to the occurrence of many events and actual results beyond our control, and the timing of events is subject to a number of factors that involve substantial known and unknown risks. may differ materially from those suggested or implied by such forward-looking statements. Uncertainty. Factors that may affect our success are disclosed in more detail in our most recent public filings with the Securities and Exchange Commission (“SEC”), including our Annual Report on Form 10-K. Masu.
Media Contact: Isabella Monteparte (imonteparte@genefic.com)
